BiotechTube

Semaglutide Treatment + Sitagliptin 100mg

ApprovedUNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Liver Transplant; Complications

Conditions

Liver Transplant; Complications, Diabetes Mellitus, NASH - Nonalcoholic Steatohepatitis, NAFLD

Trial Timeline

Oct 26, 2022 → Dec 1, 2024

NCT ID
NCT05195944

About Semaglutide Treatment + Sitagliptin 100mg

Semaglutide Treatment + Sitagliptin 100mg is a approved stage product being developed by Novo Nordisk for Liver Transplant; Complications. The current trial status is unknown. This product is registered under clinical trial identifier NCT05195944. Target conditions include Liver Transplant; Complications, Diabetes Mellitus, NASH - Nonalcoholic Steatohepatitis.

What happened to similar drugs?

9 of 20 similar drugs in Liver Transplant; Complications were approved

Approved (9) Terminated (0) Active (11)
🔄GODEX + PlaceboCelltrionPhase 3
🔄peginterferon alfa-2a 180μg + peginterferon alfa-2a 90μg + ribavirinChugai PharmaceuticalPhase 3
✅Advagraf + Prograf + PrografAstellas PharmaApproved
✅Prograf + AdvagrafAstellas PharmaApproved
✅ADVAGRAF®Astellas PharmaApproved
🔄Prograf + MR4Astellas PharmaPhase 3
🔄tacrolimusAstellas PharmaPhase 3

Hype Score Breakdown

Clinical
20
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05195944ApprovedUNKNOWN

Competing Products

20 competing products in Liver Transplant; Complications

See all competitors
ProductCompanyStageHype Score
LanifibranorInventivaPhase 2
29
GODEX + PlaceboCelltrionPhase 3
47
peginterferon alfa-2a 180μg + peginterferon alfa-2a 90μg + ribavirinChugai PharmaceuticalPhase 3
40
exatecan mesylateDaiichi SankyoPhase 2
35
TacrolimusAstellas PharmaPre-clinical
26
ATG (Fresenius Biotech)Astellas PharmaPhase 2
27
Advagraf + Prograf + PrografAstellas PharmaApproved
43
Prograf + AdvagrafAstellas PharmaApproved
43
ADVAGRAF®Astellas PharmaApproved
43
Prograf + MR4Astellas PharmaPhase 3
40
tacrolimus modified release (MR) + tacrolimusAstellas PharmaPhase 2
35
tacrolimus modified release (MR) + tacrolimusAstellas PharmaPhase 2
35
tacrolimusAstellas PharmaPhase 3
40
Prograf-XL + Prograf + MMFAstellas PharmaPhase 3
40
micafungin + fluconazole + liposomal amphotericin B + caspofunginAstellas PharmaPhase 3
40
Tacrolimus granules + Tacrolimus granulesAstellas PharmaApproved
43
FK506E (modified release tacrolimus) + Prograf (tacrolimus)Astellas PharmaPhase 3
40
FK778Astellas PharmaPhase 2
35
Tacrolimus modified-release + PrografAstellas PharmaPhase 3
40
Advagraf + PrografAstellas PharmaApproved
39